Head to Head Survey: Anteris Technologies Global (NASDAQ:AVR) and Coloplast A/S (OTCMKTS:CLPBY)

Coloplast A/S (OTCMKTS:CLPBY) and Anteris Technologies Global (NASDAQ:AVR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares Coloplast A/S and Anteris Technologies Global”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coloplast A/S	$4.13 billion	3.44	$538.49 million	$0.14	45.00
Anteris Technologies Global	$1.91 million	462.75	-$94.14 million	($2.23)	-4.07

Coloplast A/S has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Coloplast A/S and Anteris Technologies Global, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coloplast A/S	1	1	0	1	2.33
Anteris Technologies Global	1	0	4	0	2.60

Anteris Technologies Global has a consensus price target of $16.00, indicating a potential upside of 76.21%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, analysts plainly believe Anteris Technologies Global is more favorable than Coloplast A/S.

Profitability

This table compares Coloplast A/S and Anteris Technologies Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coloplast A/S	7.46%	31.96%	10.20%
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%

Volatility & Risk

Coloplast A/S has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

Summary

Coloplast A/S beats Anteris Technologies Global on 8 of the 13 factors compared between the two stocks.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.